Top 10 Abstracts from ASCO 2020 with Milind Javle

The 5th annual CCA Summit, held October 19-21, 2023, in Scottsdale, AZ, was a very successful meeting by all measures and has gradually become one of the key scientific meetings in biliary tract cancers.

As we approach the fall season, it is wonderful to reflect on some of the amazing research presented this year, most recently at the ASCO 2023 annual meeting. One of the major highlights of ASCO this year included the results of HER2/neu-directed novel therapies in biliary cancer. Shubham Pant, MD, MBBS, from MD Anderson Cancer Center, presented the results of the HERIZON-1 clinical trial of the bispecific antibody zanidatamab in HER2/neu-expressing biliary cancers.

Researchers explore the impact of gemcitabine/cisplatin plus pembrolizumab on patient health-related quality of life in a subanalysis of the KEYNOTE-966 study.

Researchers in the ADJUBIL study plan to assess the clinical activity of the immunotherapies durvalumab and tremelimumab with or without capecitabine in patients with resectable biliary tract cancer in the adjuvant setting.

Basket study investigated targeted therapies as second-line treatment for patients with biliary tract cancer who are HER2-positive.

Researchers are investigating novel combination therapies, including immunotherapies and poly-ADP ribose polymerase (PARP) inhibitors, to improve survival in patients with biliary tract cancer; here, the BilT-02 study is summarized.

Preliminary results from the phase 2b HERIZON-BTC-01 study investigating the efficacy of zanidatamab in patients with HER2-positive biliary tract cancer are presented.

A subanalysis of the STAMP trial examines the clinical impact of using circulating tumor DNA for detecting molecular residual disease and monitoring in patients with CCA in the adjuvant setting.

The researchers found that EGFR amplifications and FGFR3 fusions may be important predictive biomarkers in biliary tract cancer (BTC) and may serve as a future target for systemic anticancer therapy in patients with BTC.